BREAK COVID: COVID-19 breakthrough infections and correlates of protection

BREAK COVID: COVID-19 breakthrough infections and correlates of protection - BREAK COVID

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON53358

Enrollment

550

Registered

2023-02-22

Start date

2023-03-30

Completion date

Unknown

Last updated

2024-04-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

coronavirus COVID-19

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Over 18 years of age Willing to share vaccination and infection records with the investigators

Exclusion criteria

Exclusion criteria: Not fulfilling the inclusing criteria

Design outcomes

Primary

Measure	Time frame
1. Cellular and humoral correlates of protection from symptomatic and asymptomatic SARS-CoV-2 breakthrough infection after vaccination 2, Cellular and humoral correlates of protection from symptomatic and asymptomatic infection after natural infection	—

Secondary

Measure	Time frame
1. Risk of symptomatic BTI after booster vaccination, and after natural infection, with the in 2023 predominating SARS-CoV-2 variant. 2. Risk of asymptomatic BTI after booster vaccination, and after natural infection, with the in 2023 predominating SARS-CoV-2 variant 3. Other factors associated with BTI (variants, vaccine regimen; monovalent/bivalent, nasal transcriptome findings over time prior, during and 14 days after infection, immune status)	—

Measure

Time frame

1. Risk of symptomatic BTI after booster vaccination, and after natural infection, with the in 2023 predominating SARS-CoV-2 variant. 2. Risk of asymptomatic BTI after booster vaccination, and after natural infection, with the in 2023 predominating SARS-CoV-2 variant 3. Other factors associated with BTI (variants, vaccine regimen; monovalent/bivalent, nasal transcriptome findings over time prior, during and 14 days after infection, immune status)

—

Countries

Netherlands

Outcome results